Promising New Drug Combination For Patients With Sleeping Sickness

Human African trypanosomiasis (HAT) or sleeping sickness affects tens of thousands of people every year in sub-Saharan Africa. It is a fatal disease with few treatment options. According to an article in this week's issue of The Lancet, Nifurtimox in combination with eflornithine is safe, effective, and more affordable than current treatments for sleeping sickness. This new drug combination should be implemented as a matter of priority by control programmes across sub-Saharan Africa. Read more ...

Women who get less than the recommended eight hours sleep a night are at higher risk of heart disease and heart-related problems than men with the same sleeping patterns. Research by the University of Warwick and University College London has found that levels of inflammatory markers vary significantly with sleep duration in women, but not men. Read more ...

Read more ...

A study in the June 15 issue of the Journal of Clinical Sleep Medicine shows that the complaints of fatigue and tiredness in patients with obstructive sleep apnea (OSA) improved significantly with good adherence to continuous positive airway pressure (CPAP) therapy, suggesting that - like the symptom of excessive daytime sleepiness - these complaints are important symptoms of OSA. Read more ...

Cephalon, Inc. (Nasdaq: CEPH) announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGIL(R) (armodafinil) Tablets [C-IV] for the indication of improved wakefulness in patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel. Read more ...